- |||||||||| fisogatinib (BLU-554) / Blueprint Medicines, ABSK012 / Abbisko
Discovery & characterization of a next-generation FGFR4 inhibitor overcoming resistant mutations (Section 35; Poster Board #19) - Mar 14, 2023 - Abstract #AACR2023AACR_8015;
ABSK012, presented here by Abbisko Therapeutics, is a highly potent, selective, and next-generation small molecule FGFR4 inhibitor overcoming FGFR4 mutations resistant to first-generation inhibitors. Its superior preclinical profile supports its fast-track development into clinic.
|
